



Pfizer Inc.
235 East 42nd Street
New York, NY 10017-5755

Pfizer Pharmaceuticals

Dear Healthcare Provider,

We are writing to inform you of the measures Pfizer is taking to preserve patient access to Camptosar® (irinotecan hydrochloride).

As you know, Congress passed the Medicare Prescription Drug, Improvement and Modernization Act last year. This new legislation presents significant challenges for the oncology community as we transition to a new reimbursement environment. Many of you have reported to us that the current CMS-published reimbursement rates for Camptosar are inadequate to cover your acquisition costs for Camptosar. Pfizer has met with CMS to explain the situation and is committed to working with CMS to find joint solutions to this problem. Although CMS is quite concerned, they are unable to provide critical, immediate relief. Therefore, Pfizer has decided to take unilateral action to support your current and potential Camptosar patients.

Effective January 27, 2004, Pfizer has reduced the price of Camptosar by approximately 6.1%. The new published list price of Camptosar will be \$245.46 (2ml/vial) and \$613.65 (5ml/vial). We urge you to follow up with your Pfizer- authorized distributors to realize this new price.

Pfizer remains profoundly committed to ensuring that community healthcare teams and their patients have access to lifesaving treatments. We trust this action will improve access to Camptosar for your patients.

Respectfully,

A handwritten signature in black ink, appearing to read "Leena Das-Young".

Leena Das-Young, Pharm. D.
U.S. Team Leader Camptosar